Hematopoietic growth factors: ESMO recommendations for the applications.

Greil R, Psenak O, Roila F Ann Oncol. 2008 May,19 Suppl 2:ii116-8. doi: 10.1093/annonc/mdn107.

MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.

Gryshchenko I, Hofbauer S, Stoecher M, Daniel PT, Steurer M, Gaiger A, Eigenberger K, Greil R, Tinhofer I. J Clin Oncol. 2008 May 10,26(14):2252-7. doi: 10.1200/JCO.2007.11.5212.

Chemotherapy in gastric cancer.

Wöll E, Devries A, Eisterer W, Hejna M, Keil F, Stein H, Zacherl J, Greil R. Anticancer Res. 2008 Mar-Apr,28(2B):1213-9.

Erythropoietins in cancer patients: ESMO recommendations for use.

Greil R, Thödtman R, Roila F Ann Oncol. 2008 May,19 Suppl 2:ii113-5. doi: 10.1093/annonc/mdn106.

The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer.

Bartsch R, Mlineritsch B, Gnant M, Niernberger T, Pluschnig U, Greil R, Wenzel C, Sevelda P, Thaler J, Rudas M, Pober M, Zielinski CC, Steger GG Breast Cancer Res Treat. 2009 May,115(2):373-80. doi: 10.1007/s10549-008-0132-0. Epub 2008 Jul 26.

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.

Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kässmann H, Piswanger-Sölkner JC, Seifert M, Ploner F, Menzel C, Dubsky P, Fitzal F, Bjelic-Radisic V, Steger G, Greil R, Marth C, Kubista E, Samonigg H, Wohlmuth P, Mittlböck M, Jakesz R Lancet Oncol. 2008 Sep,9(9):840-9. doi: 10.1016/S1470-2045(08)70204-3. Epub 2008 Aug 19.

SNP309 as predictor for sensitivity of CLL cells to the MDM2 inhibitor nutlin-3a.

Seyfried I, Hofbauer S, Stoecher M, Greil R, Tinhofer I. Blood. 2008 Sep 1,112(5):2168, author reply 2169. doi: 10.1182/blood-2008-05-158634.

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG N Engl J Med. 2008 Aug 28,359(9):906-17. doi: 10.1056/NEJMoa0801479.

Biweekly oxaliplatin and irinotecan chemotherapy in advanced gastric cancer. A first-line multicenter phase II trial of the Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT).

Wöll E, Kühr T, Eisterer W, Gattringer K, Greil R, Zabernigg A, Hilbe W, Thaler J. Anticancer Res. 2008 Sep-Oct,28(5B):2901-5.

Mitochondrial phosphate-carrier deficiency: a novel disorder of oxidative phosphorylation.

Mayr JA, Merkel O, Kohlwein SD, Gebhardt BR, Böhles H, Fötschl U, Koch J, Jaksch M, Lochmüller H, Horvath R, Freisinger P, Sperl W. American Journal of Human Genetics. 2007 Mar,80(3):478-84. Epub 2007 Jan 10.